Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$33.49

0.38 (1.15%)

, MRK

Merck

$54.90

(0.00%)

06:32
02/15/18
02/15
06:32
02/15/18
06:32

AstraZeneca, Merck: FDA grants Orphan Drug Designation for selumetinib

AstraZeneca (AZN( and Merck (MRK) announced that the U.S. FDA has granted Orphan Drug Designation for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1. The potential benefit of selumetinib in NF1 is being explored in the U.S. National Cancer Institute-sponsored phase 1/2 SPRINT trial in pediatric patients with symptomatic NF1-related PNs. Phase II trial results are expected later in 2018.

AZN

AstraZeneca

$33.49

0.38 (1.15%)

MRK

Merck

$54.90

(0.00%)

  • 15

    Feb

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 04

    Apr

  • 23

    Apr

  • 23

    Oct

AZN AstraZeneca
$33.49

0.38 (1.15%)

01/22/18
WELS
01/22/18
NO CHANGE
WELS
Underperform
Teva can't afford more pipeline setbacks, says Wells Fargo
After Teva (TEVA) reported that its Phase 3 registration study evaluating subcutaneously administered reslizumab in a pre-filled syringe did not meet its primary endpoint, Wells Fargo analyst David Maris said he believes this puts Teva at a disadvantage versus peers AstraZeneca (AZN) and GlaxoSmithKline (GSK) at a time when Teva cannot afford more pipeline setbacks. Subcutaneous reslizumab was not a major focus, but the news is still "another disappointment," said Maris, who keeps an Underperform rating on Teva shares.
01/02/18
ADAM
01/02/18
NO CHANGE
Target $77
ADAM
Buy
ANI Pharmaceuticals best positioned in emerging generics space, says Canaccord
Canaccord analyst Dewey Steadman said ANI Pharmaceuticals (ANIP) is one of the best positioned names in the emerging generics space. He noted the company has a basket of additional branded tail assets from its AstraZeneca (AZN) acquisitions, additional cash on hand and credit facilities for future transactions, and a solid core business. Steadman reiterated his Buy rating and raised his price target to $77 from $75 on ANI Pharmaceuticals shares.
12/29/17
12/29/17
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. AstraZeneca (AZN) upgraded to Overweight from Neutral at JPMorgan with analyst James Gordon saying the company's "superior medium-term growth outlook," which is twice the peer average, warrants a 25% sector premium. 2. PriceSmart (PSMT) upgraded to Outperform from Market Perform at IFS Securities. 3. Novo Nordisk (NVO) upgraded to Neutral from Underweight at JPMorgan with analyst Richard Vosser saying he expects "strong" oral semaglutide Phase III newsflow in 2018. 4. Syntel (SYNT) downgraded to Underperform from Market Perform at Wells Fargo with analyst Ed Caso saying he sees the company's "weak" positioning for the ongoing shift in information technology demand from "legacy" low-cost offshore-centric software services to more onshore-necessary "digital" solutions as dragging down its growth and margins. 5. RioCan REIT downgraded to Sector Perform from Outperform at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/29/17
JPMS
12/29/17
UPGRADE
JPMS
Overweight
AstraZeneca upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst James Gordon upgraded AstraZeneca to Overweight and raised his price target for the shares to 55 pounds from 48 pounds. The company's "superior medium-term growth outlook," which is twice the peer average, warrants a 25% sector premium, Gordon tells investors in a research note. He believes downside risk around the Mystic trial failure and "overly high base business expectations" have now lessened with consensus earnings forecasts declining 15%. The analyst expects AstraZeneca to return to sales growth in 2018, even without further immuno-oncology trial success. Astra has 10 Phase III readouts, with fairly low expectations across the board, Gordon argues.
MRK Merck
$54.90

(0.00%)

02/14/18
BMOC
02/14/18
NO CHANGE
Target $65
BMOC
Outperform
Merck price target lowered to $65 from $70 at BMO Capital
BMO Capital analyst Alex Arfaei lowered his price target on Merck to $65 after the company discontinued its APECS study. The analyst sees this as "another setback that increases Merck's dependence on Keytruda" and contends that the company needs other meaningful drivers. Arfaei keeps his Outperform rating based on his confidence in Keytruda growth and Merck's Immuno-oncology execution.
01/17/18
BMOC
01/17/18
NO CHANGE
Target $72
BMOC
Outperform
Merck price target raised to $72 from $68 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Merck to $72 from $68, keeping his Outperform rating following a 6% move higher in the stock price yesterday. The analyst says he remains bullish based on a "meaningful upside for Keytruda" and better performance from supporting drug franchises such as Gardasil. Arfaei warns however that while Keytruda has solidified its lead in non-small cell lung cancer market, it remains the company's only major growth driver while immuno oncology becomes increasingly more competitive.
01/16/18
01/16/18
UPGRADE
Target $72

Buy
Merck upgraded on earlier than expected Keytruda trial success at SunTrust
As previously reported, SunTrust analyst John Boris upgraded Merck to Buy from Hold, stating that he had expected positive data from the Keynote-189 trial but that the positive results on Progression Free Survival and Overall Survival came earlier than expected. This timing should enable Merck to maintain its first-mover advantage in first-line non-squamous Non-Small Cell Lung Cancer, or NSCLC, in the U.S. and file in the EU, Boris tells investors. He raised his price target to $72 from $54 on Merck shares, which are up $4.09, or 7%, to $62.75 in morning trading.
01/16/18
RHCO
01/16/18
UPGRADE
RHCO
Buy
Merck upgraded to Buy from Hold at SunTrust

TODAY'S FREE FLY STORIES

11:50
03/21/19
03/21
11:50
03/21/19
11:50
General news
Treasury's $95 B 4- and 8-week bill sales were mixed »

Treasury's $95 B 4-…

EVH

Evolent Health

$13.74

0.585 (4.45%)

11:47
03/21/19
03/21
11:47
03/21/19
11:47
Recommendations
Evolent Health analyst commentary  »

Kentucky Medicaid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$103.54

1.2 (1.17%)

11:45
03/21/19
03/21
11:45
03/21/19
11:45
Options
PayPal call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$37.75

-0.12 (-0.32%)

11:38
03/21/19
03/21
11:38
03/21/19
11:38
Conference/Events
Boston Scientific management to meet with UBS »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 18

    May

  • 28

    May

ORHOF

Origin House

$0.00

(0.00%)

, ACB

Aurora Cannabis

$9.60

-0.2 (-2.04%)

11:38
03/21/19
03/21
11:38
03/21/19
11:38
On The Fly
Rising High: An exclusive talk with cannabis brands company Origin House »

In this edition of…

ORHOF

Origin House

$0.00

(0.00%)

ACB

Aurora Cannabis

$9.60

-0.2 (-2.04%)

APHA

Aphria

$9.98

-0.15 (-1.48%)

CVSI

CV Sciences

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

CRON

Cronos Group

$20.67

-0.59 (-2.78%)

CGC

Canopy Growth

$45.90

-0.9 (-1.92%)

TLRY

Tilray

$69.93

-0.7 (-0.99%)

IGC

India Globalization Capital

$2.02

0.12 (6.32%)

KNHBF

ICC International Cannabis

$0.00

(0.00%)

ORTFD

Biome Grow

$0.00

(0.00%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

OGRMF

Organigram

$0.00

(0.00%)

KSHB

KushCo Holdings

$0.00

(0.00%)

MMNFF

MedMen

$0.00

(0.00%)

ELLXF

Elixinol Global

$0.00

(0.00%)

PLNHF

Planet 13 Holdings

$0.00

(0.00%)

KHRNF

Khiron Life Sciences

$0.00

(0.00%)

LHSIF

Liberty Health Sciences

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

FB

Facebook

$164.56

-0.91 (-0.55%)

11:37
03/21/19
03/21
11:37
03/21/19
11:37
Hot Stocks
Facebook says issues fixed after finding user passwords readable by employees »

Facebook's VP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 03

    Apr

  • 04

    Apr

11:36
03/21/19
03/21
11:36
03/21/19
11:36
General news
8-Week Bill Auction Total Amount data reported »

8-Week Bill Auction Total…

11:36
03/21/19
03/21
11:36
03/21/19
11:36
General news
4-Week Bill Auction Total Amount data reported »

4-Week Bill Auction Total…

11:35
03/21/19
03/21
11:35
03/21/19
11:35
General news
U.S. equities have ramped higher »

U.S. equities have ramped…

SRC

Spirit Realty

$37.60

0.54 (1.46%)

11:31
03/21/19
03/21
11:31
03/21/19
11:31
Conference/Events
Spirit Realty management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

  • 09

    May

WFC

Wells Fargo

$49.32

-1.07 (-2.12%)

, GS

Goldman Sachs

$193.30

-0.97 (-0.50%)

11:27
03/21/19
03/21
11:27
03/21/19
11:27
Periodicals
Wells Fargo in talks to hire former Goldman co-COO as its CEO, NY Post reports »

Wells Fargo (WFC) is in…

WFC

Wells Fargo

$49.32

-1.07 (-2.12%)

GS

Goldman Sachs

$193.30

-0.97 (-0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Apr

  • 23

    Apr

  • 28

    May

  • 13

    Jul

  • 12

    Oct

FB

Facebook

$165.28

-0.19 (-0.11%)

11:26
03/21/19
03/21
11:26
03/21/19
11:26
Periodicals
Facebook stored user passwords in plain text for years, KrebsOnSecurity says »

Hundreds of millions of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 03

    Apr

  • 04

    Apr

WDC

Western Digital

$50.60

3.43 (7.27%)

11:25
03/21/19
03/21
11:25
03/21/19
11:25
Options
Western Digital call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:25
03/21/19
03/21
11:25
03/21/19
11:25
General news
Treasury Action: the yield curve is a big topic of conversation »

Treasury Action: the…

11:25
03/21/19
03/21
11:25
03/21/19
11:25
Conference/Events
JPMorgan medtech analyst to hold a group luncheon »

Medtech Analyst Marcus…

PEB

Pebblebrook Hotel

$32.07

0.34 (1.07%)

11:21
03/21/19
03/21
11:21
03/21/19
11:21
Conference/Events
Pebblebrook Hotel management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 28

    Mar

  • 29

    Mar

BIIB

Biogen

$230.10

-90.37 (-28.20%)

11:21
03/21/19
03/21
11:21
03/21/19
11:21
Downgrade
Biogen rating change  »

Biogen downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 24

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

AGCO

Agco

$68.12

0.15 (0.22%)

11:20
03/21/19
03/21
11:20
03/21/19
11:20
Conference/Events
Agco management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

IEX

IDEX Corp.

$150.73

2.31 (1.56%)

11:19
03/21/19
03/21
11:19
03/21/19
11:19
Conference/Events
IDEX Corp. management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

ITGR

Integer

$85.72

0.28 (0.33%)

11:18
03/21/19
03/21
11:18
03/21/19
11:18
Conference/Events
Integer management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 02

    Apr

  • 03

    Apr

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
03/21/19
03/21
11:17
03/21/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EB

Eventbrite

$20.84

0.75 (3.73%)

11:16
03/21/19
03/21
11:16
03/21/19
11:16
Conference/Events
Eventbrite management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
03/21/19
03/21
11:16
03/21/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCL

Royal Caribbean

$116.64

0.55 (0.47%)

11:15
03/21/19
03/21
11:15
03/21/19
11:15
Options
Royal Caribbean put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
03/21/19
03/21
11:15
03/21/19
11:15
General news
7-Yr Note Announcement CUSIP Number data reported »

7-Yr Note Announcement…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.